CHENNAI: A patient with moderate signs of Covid-19 and also has a higher risk of developing serious complications because of present comorbidities obtained a monoclonal antibody treatment in Chennai’s Kauvery Hospital on Friday.
In a discharge, the hospital explained that the individual that received the remedy had been a cancer patient also recently diagnosed with premature onset of renal failure, which then places the individual in a higher risk of acute complications of Covid-19.
Dr Anita Ramesh, senior adviser, clinical oncology, Kauvery Hospital, stated the antibody cocktail medication is a mixture of Casirivimab and Imdevimab, two carcinogens that are lab-engineered which can mimic the immune system’s capacity to resist against this dangerous pathogen.
“Given to these individuals that are in their first phase of Covid-19 with moderate symptoms, this can reduce the multiplication of this virus, thus preventing serious sickness and disease,” she explained.
When provided to patients continuously over ten days prior to the start of the first symptoms of this disease, this therapy may reduce or even prevent the need for hospitalization by 70 per cent.
The medication is administered via the intravenous or subcutaneous (below the skin) path, via an infusion or injection and becomes more active shortly after from the human body.
“Children over 12 decades, with moderate symptoms, may likewise be granted the medication safely and efficiently,” the physician stated.
Another town hospital, Gleneagles Global Health City, has partnered with Cipla and established the antibody-drug cocktail created by Roche.
The drug received approval in the Central Drugs Standards Control Organisation.